Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Docusate sodium may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
FOR What Docusol Solution is Docusol Solution contains the active substance docusate sodium. This medicine is a laxative. It belongs to a group of medicines called 'stool softeners'. Docusol Solution is used to prevent and treat constipation in adults and children aged over 12 years. How Docusol Solution works Docusol Solution softens the stools (faeces). It does this by increasing the amount of water within the stools (faeces). This makes your bowel movements easier and reduces the strain required to pass stools. It helps you when:
E DOCUSOL SOLUTION
Docusol Solution contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per 5 mL dose, that is to say essentially 'sodium-free'.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
3. HOW TO TAKE DOCUSOL SOLUTION
Swallow each dose followed by plenty of water or flavoured drink e.g. milk or orange juice. If you take more Docusol Solution than you should If you accidentally take more Docusol Solution than you should, drink lots of water and contact your nearest hospital casualty department, or tell your doctor immediately. If you forget to take Docusol Solution As soon as you remember, take a dose and then continue the normal course of treatment. Do not take a double dose to make up for a forgotten dose.
What Docusol Solution contains
If you have any further questions on the use of this product, ask the pharmacist or doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If any of the following happen, stop taking Docusol Solution and talk to your pharmacist or doctor as soon as possible: Rare: may affect up to 1 in 1,000 people
DOCUSOL SOLUTION This medicinal product does not require any special storage conditions. Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date that is stated on the bottle label and carton after EXP. The expiry date refers to the last day of that month. 4/DA(IC)/05/2310/822.v4
Do not take Docusol Solution if:
Always take this medicine exactly as described in this leaflet or as your pharmacist or doctor has told you. Check with your pharmacist or doctor if you are not sure.
Do not take this medicine if any of the above applies to you. If you are not sure, talk to your pharmacist or doctor before taking this medicine.
Do not give Docusol Solution to children aged 12 years and under. You should feel more comfortable within 1 to 2 days of treatment. Talk to your pharmacist or doctor if you end up taking Docusol Solution every day.
Warnings and precautions As with all laxatives, do not take Docusol Solution every day for a long time. Talk to your pharmacist or doctor if:
How much to take Adults and children aged over 12 years
The active substance in Docusol Constipation Relief is docusate sodium.
Medicines with the same active substance, strength and form include: Norgalax. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Docusol Constipation Relief, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Prevention and treatment of chronic constipation. Prevention of hard dry stools and reduction of straining at stools in the presence of conditions like haemorrhoids and anal fissures.
Posology
Adults: 10 mL three times a day. Take as a single dose followed by plenty of water or flavoured drink e.g. milk or orange juice. Maximum daily dose 30 mL.
Treatment should be commenced with large doses which should be decreased as the condition of the patient improves.
Elderly: There is no evidence to suggest that an adjustment of the dosage is necessary in the elderly.
Paediatric population
Children aged 6 months to 12 years use Docusol Paediatric 12.5 mg/ 5 ml Solution.
Duration of treatment
The patient should be advised to consult a physician when constipation persists or worsens during treatment or when laxatives are needed for a long period of time.
Method of administration
Oral use.
Docusol Constipation Relief 50 mg/5 ml Solution should not be taken:
• by patients with a known hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• in the presence of abdominal pain, intestinal obstruction, nausea or if vomiting occurs.
Paediatric population
Docusol Constipation Relief 50 mg/5 ml Solution is not recommended for children aged 12 years and under.
Docusol Constipation Relief 50 mg/5 ml Solution contains sorbitol.
This medicine contains 1290 mg sorbitol in each 5 mL dose. Sorbitol is a source of fructose so should not be given to patients who have an intolerance to some sugars or have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose. Sorbitol may cause gastrointestinal discomfort and mild laxative effect.
Docusol Constipation Relief 50 mg/5 ml Solution contains 5 mg of methyl p-hydroxybenzoate in each 5 mL dose and 2.5 mg of propyl p-hydroxybenzoate in each 5 mL dose. May cause allergic reactions (possibly delayed).
Docusol Constipation Relief 50 mg/5 ml Solution contains aspartame.
This medicine contains 15 mg aspartame in each dose (5 mL) . Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.
Docusol Constipation Relief 50 mg/5 ml Solution contains sodium benzoate.
This medicine contains 5 mg sodium benzoate in each dose (5 mL).
Docusol Constipation Relief 50 mg/5 ml Solution contains sodium.
This medicine contains less than 1 mmol sodium (23 mg) per 5 mL dose, that is to say essentially 'sodium-free'.
Docusol Constipation Relief 50 mg/5 ml Solution should not be taken concurrently with mineral oil. Anthraquinone derivatives should be taken in reduced doses, if administered with Docusol Constipation Relief 50 mg/5 ml Solution as their absorption is increased.
Pregnancy
There is inadequate evidence of safety of the drug in human pregnancy, nor is there evidence from animal work that it is free from hazard, but it has been in wide use for many years without apparent ill consequence. Use in pregnancy only if the benefits outweigh the potential risks.
Breastfeeding
Docusate sodium is excreted in breast milk and should therefore be used with caution in lactating mothers.
None known.
Frequencies are defined as follows: Very common (≥ 1/10); common (≥ 1/100 to ≤ 1/10); uncommon (≥ 1/1,000 to ≤ 1/100); rare (≥ 1/10,000 to ≤ 1/1,00); very rare (≤ 1/10,000), not known (cannot be estimated from the available data).
Gastrointestinal disorders:
Rare: diarrhoea, nausea, abdominal cramps.
Skin and subcutaneous tissue disorders:
Not known: skin rash and pruritus.
There have been spontaneous reports of burning sensation in mouth and throat following the use of docusate sodium. Patients are advised to drink plenty of water or flavoured drink after taking the solution.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit / risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
In rare cases of overdose, excessive loss of water and electrolytes should be treated by encouraging the patient to drink plenty of fluid.
Ask anything about Docusol Constipation Relief. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.